(Q34447427)

2 August 2017

1 reference

title

Lung tumor markers of cytokeratin origin: an overview (English)

1 reference

2 August 2017

Buccheri G

1

1 reference

2 August 2017

Ferrigno D

series ordinal

2

1 reference

2 August 2017

publication date

1 December 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

34 Suppl 2

1 reference

2 August 2017

page(s)

S65-9

1 reference

Serum tumour markers in lung cancer: history, biology and clinical applications

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Clinical applications of serum markers for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Cytoskeleton--plasma membrane interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Intermediate filaments as mechanical integrators of cellular space

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Cytokeratins and Tissue Polypeptide Antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Comparison of Cyfra 21–1, Tpa and Tps in Lung Cancer, Urinary Bladder Cancer and Benign Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Sequence homology between tissue polypeptide antigen (TPA) and intermediate filament (IF) proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Prognostic factors in lung cancer: tables and comments

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Prognostic value of the tissue polypeptide antigen in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

CYFRA 21-1: A new marker in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Assessment of serum CYFRA 21-1 in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

Pretreatment Evaluation of Non–Small-cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900347-6

7 January 2021

10.1016/S0169-5002(01)00347-6

Identifiers

DOI

1 reference

2 August 2017

1 reference